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background: Embolic protection devices have become standard of care during carotid artery stenting (CAS) to reduce periprocedural stroke risk. 
Distal Protection Devices (DPD) were the first and are the most commonly used devices. Proximal protection devices (PPD) avoid lesion crossing 
and thus are potentially safer. MO.MA is the only commercially available PPD in the US. This study compares MO.MA to DPD during CAS for rates of 
clinical stroke and asymptomatic periprocedural cerebral microembolization defined by diffusion weighted magnetic resonance imaging (DW-MRI) 
abnormalities.
Methods: We searched Pubmed, EMBASE and Scopus databases to identify randomized controlled trials (RCT) and case-control studies comparing 
MO.MA to DPD in patients undergoing CAS. Statistical analysis was consistent with QUORUM guidelines using RevMan 5.1.7 software. Heterogeneity 
was defined as I2 values > 25%. Sensitivity analysis was also performed.
results:6 studies provided 3414 patients distributed among the MO.MA (307) and DPD group (3107). RCT data of microembolization utilizing 
MO.MA (see figure) were associated with a lower incidence of new cerebral lesions compared to DPD. Death and stroke were rare in both groups 
occurring in less than 1% of patients.
conclusion: MO.MA is associated with a lower incidence of new embolic cerebral lesions as assessed by DW-MRI. The clinical significance of this 
finding is yet to be defined. MO.MA and DPD were safe with the stroke rate in both groups being lower than historical series.
 
